MX2024012966A - Usos de los agonistas del receptor farnesoide x - Google Patents

Usos de los agonistas del receptor farnesoide x

Info

Publication number
MX2024012966A
MX2024012966A MX2024012966A MX2024012966A MX2024012966A MX 2024012966 A MX2024012966 A MX 2024012966A MX 2024012966 A MX2024012966 A MX 2024012966A MX 2024012966 A MX2024012966 A MX 2024012966A MX 2024012966 A MX2024012966 A MX 2024012966A
Authority
MX
Mexico
Prior art keywords
farnesoid
receptor agonists
diseases
ameliorating
disorders
Prior art date
Application number
MX2024012966A
Other languages
English (en)
Spanish (es)
Inventor
Thomas Capozza
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of MX2024012966A publication Critical patent/MX2024012966A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2024012966A 2022-04-21 2024-10-21 Usos de los agonistas del receptor farnesoide x MX2024012966A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263333287P 2022-04-21 2022-04-21
US202263381752P 2022-10-31 2022-10-31
PCT/US2023/019448 WO2023205447A2 (en) 2022-04-21 2023-04-21 Uses of farnesoid x receptor agonists

Publications (1)

Publication Number Publication Date
MX2024012966A true MX2024012966A (es) 2024-11-08

Family

ID=88420596

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024012966A MX2024012966A (es) 2022-04-21 2024-10-21 Usos de los agonistas del receptor farnesoide x

Country Status (10)

Country Link
US (1) US20250288600A1 (enExample)
EP (1) EP4511012A2 (enExample)
JP (1) JP2025513289A (enExample)
KR (1) KR20250006156A (enExample)
CN (1) CN119136794A (enExample)
AU (1) AU2023257308A1 (enExample)
CA (1) CA3249500A1 (enExample)
IL (1) IL315941A (enExample)
MX (1) MX2024012966A (enExample)
WO (1) WO2023205447A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4611888A1 (en) * 2022-10-31 2025-09-10 Intercept Pharmaceuticals, Inc. Uses of farnesoid x receptor agonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3777863A1 (en) * 2014-09-12 2021-02-17 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
PE20180690A1 (es) * 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
EP3426348B1 (en) * 2016-03-11 2021-05-05 Intercept Pharmaceuticals, Inc. 3-desoxy derivative and pharmaceutical compositions thereof
JP7224307B2 (ja) * 2017-06-23 2023-02-17 インターセプト ファーマシューティカルズ， インコーポレイテッド 胆汁酸誘導体の調製のための方法及び中間体

Also Published As

Publication number Publication date
KR20250006156A (ko) 2025-01-10
CN119136794A (zh) 2024-12-13
CA3249500A1 (en) 2023-10-26
WO2023205447A2 (en) 2023-10-26
IL315941A (en) 2024-11-01
US20250288600A1 (en) 2025-09-18
JP2025513289A (ja) 2025-04-24
EP4511012A2 (en) 2025-02-26
WO2023205447A3 (en) 2024-04-04
AU2023257308A1 (en) 2024-10-10

Similar Documents

Publication Publication Date Title
MX2025003987A (es) Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos
PH12021553082A1 (en) Prmt5 inhibitors
ZA202100208B (en) Heterocyclic and heteroaryl compounds for treating huntington's disease
GEP20257750B (en) 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors
MX2023001917A (es) Inhibidores de la fosfatasa shp2 y metodos para su uso.
PH12022550399A1 (en) MTA-Cooperative PRMT5 Inhibitors
CR20200263A (es) Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5
MX2020014315A (es) Compuestos de heteroarilo para tratar la enfermedad de huntington.
PH12023552079A1 (en) Cdk2 inhibitors and methods of using the same
MX2023004802A (es) Compuestos espiro heterocíclicos y métodos de uso.
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
MX2021009521A (es) Inhibidores de dihidroorotato deshidrogenasa.
PH12021550743A1 (en) Boron containing pde4 inhibitors
MX2024012966A (es) Usos de los agonistas del receptor farnesoide x
ZA202109182B (en) Natriuretic peptide receptor 1 antibodies and methods of use
SA520420909B1 (ar) تثبيط بروتين رابط لـ creb (cbp)
MX2023009060A (es) Antagonistas de gpr84 y usos de estos.
PH12021551304A1 (en) Tyrosine kinase inhibitors, compositions and methods there of
MX2023001296A (es) Composiciones y metodos para tratar enfermedades y trastornos.
PH12022550491A1 (en) Perk inhibiting pyrrolopyrimidine compounds
ZA202107777B (en) Voruciclib polymorphs and methods of making and using thereof
PH12022550497A1 (en) Perk inhibiting compounds
MX2024014435A (es) Compuestos heterociclicos y heteroarilo para el tratamiento de la enfermedad de huntington
WO2024026486A3 (en) Cdk2 inhibitors and methods of using the same
WO2024026479A3 (en) Cdk2 inhibitors and methods of using the same